Cancer最新文献

{"title":"Long-term outcomes and patterns of failure in patients with thymic malignancies treated with surgery and radiation therapy","authors":"Oded Icht MD,&nbsp;Inbar Nardi-Agmon MD,&nbsp;Paaladinesh Thavendiranathan MD, SM,&nbsp;Shaf Keshavjee MD,&nbsp;Amiya Agrawal MD,&nbsp;John-Michael Miro MD,&nbsp;Omar Badran MD,&nbsp;Geoffrey Liu MD,&nbsp;Xiang Y. Ye Msc,&nbsp;B. C. John Cho MD, PhD,&nbsp;Andrea Bezjak MD,&nbsp;Andrew Hope MD","doi":"10.1002/cncr.70595","DOIUrl":"https://doi.org/10.1002/cncr.70595","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The role of peri-operative radiation therapy in thymic epithelial tumors remains controversial, and randomized data are lacking. The authors evaluated recurrence patterns, pathologic predictors of recurrence, and long-term survival among patients who underwent surgery and received peri-operative radiation at a high-volume tertiary center.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The authors conducted a retrospective cohort study of patients who had thymic malignancies treated surgically between 2004 and 2021. Clinical, pathologic, and treatment data were collected. Outcomes were assessed using Kaplan–Meier and Cox regression methods, and propensity score overlap weighting was applied to adjust for baseline differences between the radiation and no-radiation groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In total, 360 patients were included, of whom 175 (48.6%) received peri-operative radiation. Among irradiated patients, 62 (35.4%) developed recurrence, most commonly in the pleura (76%); in-field recurrences were rare (5%). Tumor invasiveness was the strongest predictor of recurrence, particularly vascular invasion (odds ratio, 6.0; 95% confidence interval, 2.3–15.7). Histologic subtype was not associated with recurrence. Survival did not differ between groups on unadjusted comparison (hazard ratio, 1.02; 95% confidence interval, 0.63–1.67; <i>p</i> = .93). After overlap weighting, radiation was associated with overall survival (hazard ratio, 0.49; 95% CI, 0.26–0.90; <i>p</i> = .02).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In patients with surgically treated thymic malignancies, tumor invasiveness, especially vascular invasion, was the strongest predictor of recurrence and should guide risk stratification. Failure was predominantly pleural, with rare in-field recurrence, indicating good local control but a need for better strategies against pleural relapse. Survival benefit from peri-operative radiation remains uncertain and should be tested prospectively.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 18","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148878392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FDA grants accelerated approval to BCL-2 inhibitor sonrotoclax for mantle cell lymphoma","authors":"Leah Lawrence","doi":"10.1002/cncr.70537","DOIUrl":"10.1002/cncr.70537","url":null,"abstract":"&lt;p&gt;The US Food and Drug Administration (FDA) has granted accelerated approval to the BCL-2 inhibitor sonrotoclax (BGB-11417) for adults with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of therapy.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;“This is a next-generation selective BCL-2 inhibitor with a shorter half-life; venetoclax is also in this class,” explains Ajay K. Nooka, MD, MPH, a professor at Emory University School of Medicine in Atlanta, Georgia. “This medication has more potent BCL-2 inhibition in preclinical studies, and based on a single-arm study, has shown very early time to response with more than half of patients responding.”&lt;/p&gt;&lt;p&gt;The FDA approval is based on results of the BGB-11417-201 trial presented at the 2025 American Society of Hematology Annual Meeting &amp; Exposition.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; The trial enrolled 125 patients with confirmed MCL per the 2016 World Health Organization classification. All patients had received prior anti-CD20–based therapy and one or more Bruton tyrosine kinase (BTK) inhibitors.&lt;/p&gt;&lt;p&gt;In part 1 of the trial, patients were assigned to receive either 160 or 320 mg of sonrotoclax. The higher dose was identified as the recommended phase 2 dose. The median follow-up was 10.1 months. At the data cutoff, approximately one third of the patients were still receiving treatment.&lt;/p&gt;&lt;p&gt;The efficacy analysis included data from 103 patients assigned to a 320-mg dose of sonrotoclax. The overall response rate (ORR) per independent review committee assessment—the primary endpoint for the trial—was 52.4%, with a complete response rate of 15.5%. This is significantly higher than expected from historical controls, for which an ORR of 30% was reported.&lt;/p&gt;&lt;p&gt;The median time to response was 1.9 months, with a median duration of response of 15.8 months. Among those patients with fewer than three prior lines of therapy, the ORR was 61%. In addition, the ORR benefit was seen across patient subgroups, including those with negative prognostic factors.&lt;/p&gt;&lt;p&gt;Median progression-free survival was 6.5 months, and median overall survival was not reached.&lt;/p&gt;&lt;p&gt;“This is an oral agent, which can certainly improve the visit burden on patients as well as quality of life. They can be so effective that it leads to tumor lysis initially,” says Dr Nooka. “The dose of [sonrotoclax] needs to be ramped up to get to the RP2D [recommended phase 2 dose] dosing of 320 mg.”&lt;/p&gt;&lt;p&gt;Among those treated with 320 mg of sonrotoclax, the most common grade 3 or higher treatment-emergent adverse events were neutropenia (19.1%), thrombocytopenia (9.6%), and anemia (7.8%). Any-grade infection occurred in 39.1% of patients, with grade 3 or higher infections occurring in 16.5% of patients. Tumor lysis syndrome of grade 3 or higher occurred in 7.0% of patients, but all events resolved without sequelae, and no events resulted in death or treatment discontinuation.&lt;/p&gt;&lt;p&gt;The FDA’s prescribing information includes warni","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 17","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70537","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148862840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HERMES trial supports shortened SBRT schedule without added toxicity for patients with prostate cancer","authors":"Leah Lawrence","doi":"10.1002/cncr.70538","DOIUrl":"10.1002/cncr.70538","url":null,"abstract":"<p>Treatment with two larger doses of stereotactic body radiation therapy (SBRT) caused no additional side effects in comparison with the standard five doses of SBRT in patients with intermediate or lower high-risk prostate cancer according to findings from the HERMES trial presented at the Congress of the European Society for Radiotherapy and Oncology.<span>¹</span></p><p>Sian Cooper, MBBS, a clinical research fellow at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research in London, the United Kingdom, and her colleagues presented results from the single-center trial, which randomly assigned 46 patients to one of two SBRT regimens: 24 Gy delivered in two fractions (2F) over 8 days with a 27-Gy integrated boost to the magnetic resonance imaging (MRI)–defined tumor or 36.25 Gy in five fractions (5F) over 2 weeks (to the planning target volume) with 40 Gy administered to the prostate and the proximal 1 cm of the seminal vesicles.</p><p>The rates of cumulative grade 2+ genitourinary adverse events at 24 months were 18.2% with 2F and 25.0% with 5F. The rates of cumulative grade 2+ gastrointestinal adverse events at 24 months were 4.6% with 2F and 4.2% with 5F.</p><p>The rate of cumulative grade 2+ erectile dysfunction at 24 months was 45.5% with 2F and 73.9% with 5F.</p><p>The researchers also evaluated the International Prostate Symptom Score at the baseline and 24 months. The median scores remained largely unchanged in both treatment groups, with patients reporting minimal change in their quality of life.</p><p>Commenting on the results, Marc Bjurlin, DO, MSc, vice-chair of research and director of clinical trials in the University of North Carolina School of Medicine’s Department of Urology and a faculty member with the Lineberger Comprehensive Cancer Center in Chapel Hill, says that the data are another step in radiotherapy in support of moving toward shorter treatment schedules.</p><p>“Assuming these approaches can be done while minimizing side effects, the increase in convenience of these schedules is a win for patients and for the healthcare system,” Dr Bjurlin says.</p><p>However, he points out some limitations that should be considered when one is interpreting the data. All included patients underwent an MRI before treatment, which is not the current standard of care and could increase upfront costs and time requirements; however, this should be offset by a decrease in downstream costs due to the shorter radiation schedule.</p><p>“Other caveats are that this patient population was lower or intermediate high-risk prostate cancer, was a smaller number of patients, and was from a single institution,” Dr Bjurlin says. “This needs to be replicated on a larger scale.”</p><p>Additionally, this trial evaluated adverse events and quality of life. In the future, it will be important to look at cancer outcomes as well.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 17","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70538","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148862851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FDA approves test for molecular residual disease monitoring in patients with solid tumors","authors":"Leah Lawrence","doi":"10.1002/cncr.70539","DOIUrl":"10.1002/cncr.70539","url":null,"abstract":"&lt;p&gt;The US Food and Drug Administration (FDA) has approved Signatera CDx as a companion diagnostic for use with adjuvant atezolizumab in the treatment of muscle-invasive bladder cancer (MIBC). This is the first diagnostic approved for personalized molecular residual disease testing in patients with solid tumors.&lt;span&gt;&lt;sup&gt;1, 2&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;The Signatera test is used to identify patients who are positive for circulating tumor DNA (ctDNA) and may benefit from treatment with atezolizumab after cystectomy.&lt;/p&gt;&lt;p&gt;“This is the first test of this kind approved by the FDA in the solid tumor space and it is notable for being a predictive test, not just a prognostic test,” says Leonard J. Appleman, MD, PhD, a medical oncologist at the UPMC Hillman Cancer Center and director of the Genitourinary Cancer Disease Section at the University of Pittsburgh in Pennsylvania.&lt;/p&gt;&lt;p&gt;The tumor-informed ctDNA test was recommended based on the results of the IMvigor011 trial.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; The trial included patients with MIBC and no radiographic evidence of disease after surgery. All patients underwent serial ctDNA testing for up to 1 year, and most did so with Signatera, a tumor-informed blood test custom-built for each patient.&lt;/p&gt;&lt;p&gt;Patients who tested positive for ctDNA were then randomly assigned 2:1 to adjuvant atezolizumab or to a placebo every 4 weeks for up to 1 year. For patients assigned to adjuvant atezolizumab, the median disease-free survival was more than double that of patients in the placebo group (9.9 vs. 4.8 months). Atezolizumab reduced the risk of recurrence or death by 36% (hazard ratio [HR], 0.64; 95% CI, 0.47–0.87; &lt;i&gt;p&lt;/i&gt; = .005). There was also a significant improvement in overall survival for the atezolizumab group versus the placebo group (median, 32.8 vs. 21.1 months; HR, 0.59; 95% CI, 0.39–0.90; &lt;i&gt;p&lt;/i&gt; = .01).&lt;/p&gt;&lt;p&gt;Additional data from an exploratory subgroup analysis of the trial showed that ctDNA positivity correlated with pathologic staging at cystectomy, as it rose from 20.5% in patients with pT2N0 disease to 82.5% in patients with (y)pT3–4N+ disease.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;“Importantly, the trial allowed patients with T2 disease at the time of cystectomy, and if you look at current guidelines, adjuvant chemotherapy is recommended for patients with higher-stage disease,” says Dr Appleman. “However, there is still around a 20% chance that T2 patients will have recurrence, and you sometimes have to think about whether to give adjuvant therapy to these patients.”&lt;/p&gt;&lt;p&gt;IMvigor011 provides reassurance because regardless of stage, data showed that if the patient stayed negative for ctDNA, “they could pretty safely avoid having to undergo adjuvant treatment,” Dr Appleman says. Patients who were persistently negative for ctDNA were followed for up to 1 year, and at that time, only 5% had disease recurrence or died of any cause.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;“Now we are able to use ctDNA monitoring to identify high-","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 17","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70539","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148862770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interpreting a borderline signal in colorectal cancer screening among sexual and gender minority adults","authors":"Christos Zavos MD, PhD","doi":"10.1002/cncr.70598","DOIUrl":"10.1002/cncr.70598","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 17","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148862847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GPRC5D-targeting bispecific and trispecific antibodies in multiple myeloma: Current evidence and emerging strategies","authors":"Darren Pan MD,&nbsp;Anupama Kumar MD,&nbsp;Jodi J. Lipof MD,&nbsp;Alfred Chung MD,&nbsp;Jeffrey L. Wolf MD,&nbsp;Thomas G. Martin III MD,&nbsp;Shagun Arora MD,&nbsp;Peter H. Sayre MD,&nbsp;Ajai Chari MD","doi":"10.1002/cncr.70597","DOIUrl":"10.1002/cncr.70597","url":null,"abstract":"<p>G-protein–coupled receptor class C group 5 member D (GPRC5D) has emerged as a crucial immunotherapy target in relapsed/refractory multiple myeloma. Although the T-cell-engaging bispecific antibody talquetamab is currently the only approved anti-GPRC5D therapy, numerous promising agents are undergoing clinical evaluation. While anti-GPRC5D chimeric antigen receptor T cells show potential, this review focuses specifically on T-cell-engaging bispecific and trispecific antibodies. We highlight how GPRC5D differs clinically from B-cell maturation antigen, explore mechanisms of resistance, discuss novel therapeutic strategies including combination regimens and talquetamab as bridging therapy to chimeric antigen receptor T cells, and review key investigational T-cell engagers currently in development.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 17","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148862857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant CDK4/6 inhibitors in early-stage breast cancer: Clinical evidence and considerations for risk stratification and treatment selection","authors":"Austin D. Williams MD,&nbsp;Anna Weiss MD","doi":"10.1002/cncr.70587","DOIUrl":"https://doi.org/10.1002/cncr.70587","url":null,"abstract":"<p>Hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer is the most common biologic subtype and carries a persistent risk of recurrence, particularly in patients with high-risk, early-stage disease. Cyclin-dependent kinase 4 and 6 inhibitors, initially established as a standard component of first-line therapy in the metastatic setting based on improvements in progression-free and overall survival, have since been evaluated in the adjuvant setting. While adjuvant palbociclib did not improve invasive disease-free survival, the monarchE and NATALEE trials demonstrated that abemaciclib and ribociclib, respectively, reduce recurrence risk in patients with high-risk, early-stage disease, with emerging overall survival data further supporting their use. However, the absolute magnitude of benefit varies substantially with baseline risk, and treatment-related toxicity and adherence challenges must be considered, as approximately 20% to 25% of patients discontinue therapy before completion. The integration of these agents into clinical practice also intersects with ongoing efforts to deescalate axillary surgery, as treatment eligibility has been largely defined by anatomic staging, particularly nodal status. Available data suggest that the incremental impact of axillary surgery on identifying candidates for cyclin-dependent kinase 4 and 6 inhibition is modest, especially among the favorable-risk populations now eligible for surgical deescalation. As the field evolves, advances in molecular risk stratification, genomic profiling, and dynamic biomarkers are poised to shift treatment selection from anatomic staging toward biologically driven approaches. Multidisciplinary decision-making that integrates tumor biology, anticipated absolute benefit, toxicity, patient preferences, and surgical considerations will be essential to ensure individualized care.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 17","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The burden of male breast cancer (MBC) in the GBD Central, Eastern, and Western Europe Regions from 1990 to 2023: Results from the Global Burden of Disease Study 2023","authors":"Roberto Passera PhD,&nbsp;Elisa Fabbro PhD,&nbsp;Giulia Zamagni PhD","doi":"10.1002/cncr.70585","DOIUrl":"10.1002/cncr.70585","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>Male breast cancer (MBC) is underrepresented in cancer statistics: this study aimed to assess the burden of MBC in Central, Eastern, and Western Europe from 1990 to 2023, using data from the Global Burden of Disease (GBD) Study 2023.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Estimates from GBD 2023 were analyzed to determine the MBC incidence, mortality, and disability-adjusted life years, their all-ages and age-standardized rates, and the 1990 through 2023 annual percent change. These estimates were compared to those for the GBD Super Regions and the Socio-Demographic Index quintile countries.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In Central Europe, age-standardized incidence rates (ASIR) increased from 0.54 (0.40–0.76) to 1.05 (0.70–1.52), age-standardized mortality rates (ASMR) from 0.29 (0.25–0.34) to 0.40 (0.36–0.45), and age-standardized disability life-year rates (ASDR) from 7.19 (6.15–8.41) to 9.63 (8.52–11.07). In Eastern Europe, ASIR remained relatively stable, changing from 0.81 (0.56–1.19) to 0.60 (0.38–0.92), whereas ASMR decreased from 0.40 (0.33–0.49) to 0.21 (0.16–0.25) and ASDR from 10.54 (8.69–12.89) to 5.55 (4.52–6.85). In Western Europe, ASIR increased from 0.47 (0.33–0.67) to 0.88 (0.59–1.24), whereas ASMR (0.22 [0.19–0.25] vs. 0.24 [0.21–0.27]) and ASDR (5.20 [4.49–5.97] vs. 5.75 [4.96–6.66]) remained stable.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The burden of MBC is increasing across Europe, particularly in the Central region, with huge regional differences. Population growth and variations over time impacted on the metrics. Even with a composite European scenario, the mortality-to-incidence ratio markedly declined in the three areas.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 17","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148838742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to “Does disease ontogeny matter more than JAK2 mutation status in acute myeloid leukemia?”","authors":"Moath Albliwi MD,&nbsp;Daniel P. Nurse DO,&nbsp;Emily C. Zabor DrPH,&nbsp;John Hanna MD,&nbsp;Jessica El-Asmar MD, MPH,&nbsp;Ameed Bawwab MD,&nbsp;Hasan Abuamsha MD,&nbsp;Yomna Abu-Farsakh MD,&nbsp;Heya Batah MD,&nbsp;Asad Rauf MD,&nbsp;Joy Nakitandwe PhD,&nbsp;David S. Bosler MD,&nbsp;Prerana Bangalore Parthasarathy MS,&nbsp;Tyler Alban PhD,&nbsp;Akriti G. Jain MD,&nbsp;John C. Molina MD, MEd,&nbsp;Sophia Balderman MD,&nbsp;Abhay Singh MD, MPH,&nbsp;Aaron T. Gerds MD, MS,&nbsp;Sudipto Mukherjee MD, PhD, MPH,&nbsp;Anjali S. Advani MD,&nbsp;Hetty E. Carraway MD, MBA,&nbsp;Moaath K. Mustafa Ali MD, MPH","doi":"10.1002/cncr.70593","DOIUrl":"10.1002/cncr.70593","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 17","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148838701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does disease ontogeny matter more than JAK2 mutation status in acute myeloid leukemia?","authors":"Niveditha Suresh Babu MBBS,&nbsp;K. S. Sridevi Sangeetha BPharm, MSc, PhD","doi":"10.1002/cncr.70592","DOIUrl":"10.1002/cncr.70592","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 17","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148838746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}